Designing for Life

The only FDA-cleared patent hemostasis device and the only device capable of concomitant ipsilateral ulnar compression

Patent hemostasis should be the default strategy, regardless of the method or device used for compression of the arteriotomy. Concomitant ipsilateral ulnar artery compression is recommended to further maximize radial artery patency.
— Society of Cardiovascular and Angiography Interventions (3)
VASOBand Full Product

INTUITIVE, reducing meticulous and repeated monitoring (1)

SAFER, shown to reduce incidence of radial artery occlusion, hematoma, and rebound bleeding (1)(2)

EFFICACIOUS, proven to promote patent hemostasis (1)

The VASOBand Advantage

Reduces Radial Artery Occlusion (1)

Clinically proven to reduce the rate of Radial Artery Occlusion from 10.2% to 1.6%

 

Faster Patient Recovery

Less time needed to manage and monitor patients post-op, meaning patients go home sooner

Achieves Patent Hemostasis (1)

Clinically proven to achieve patent hemostasis 97% of the time

 

No Workflow Changes

Keeps it simple for all care teams

Reduces Rebound Bleeding (1)

Clinically proven to reduce incidence of rebound bleeding from 8.7% to 1.6%

 

Easy to Use

No additional training - ready to be used on Day 1

Reduces Hematoma (1)

Clinically proven to reduce hematoma from 6.3% to 0.8%

 

High Patient Comfort (1)

Wider band design provides high patient comfort compared with competing devices

 
 
 

Contact us.

Feel free to contact us with any questions.

References:

  1. Patel GA, Patel B, Shah, SC et al. Randomized COmparison of Isolated Radial Artery ComPrEssioN versus Radial and Ipsilateral Ulnar Artery Compression in Achieving Radial Artery Patency: OPEN-Radial Trial. J Inv Cardiol 2020.

  2. Pancholy, S. B., Bernat, I., Bertrand, O. F., & Patel, T. M. (2017). Prevention of radial artery occlusion after transradial catheterization: the PROPHET-II randomized trial. JACC: Cardiovascular Interventions, 9(19), 1992-1999.

  3. Catheter Cardiovasc Interv. 2019;1–8, See p 4, Sections 6.1 and 6.2.